Unlike most in vitro systems developed to study HIV replication, humans infected with HIV are co- infected with a variety of pathogenic and nonpathogenic microbes. Coinfections may influence the clinical outcome of either infection. For example, HIV infection accelerates the course of hepatitis C virus (HCV) related hepatic disease while persistent infection with GB virus type C (GBV-C) is associated with prolonged survival in HIV-infected individuals in all studies conducted prior to HAART. The mechanism(s) by which microbial coinfections interact to alter disease course provide insight into HIV natural history, and may identify novel therapeutic targets or assist in the development of prevention strategies. GBV-C is a member of the family Flaviviridae and GBV-C is a common infection of humans. The virus replicates in human peripheral blood mononuclear cells (PBMCs) including B and T lymphocytes (CD4+ and CD8+ subsets). Co-infection of PBMCs with GBV-C and HIV results in inhibition of HIV replication, and this is mediated in part by downregulation of HIV coreceptors and by induction of soluble antiviral factors. GBV-C inhibits the replication of both CCR5- and CXCR4-tropic HIV isolates, and inhibits diverse HIV clades from around the world. In addition, GBV-C infection appears to block CD4 expansion in people receiving IL-2 therapy and is associated with decreased T cell activation as measured by surface expression of several markers (CD38, CCR5, CD25, CD69). Addition of the envelope glycoprotein E2 reproduces some of these effects (CCR5 regulation, HIV inhibition) although it has not been thoroughly studied. Since GBV-C E2 protein, when added to cells independent of GBV-C replication mediates HIV replication inhibition, it is likely that this is mediated by interactions between E2 and its cellular receptor or receptors. To examine this hypothesis, we plan to characterize interactions between GBV-C E2 and it's cellular receptor(s), identify and validate candidate E2 receptors, determine the domains on E2 that interact with cellular receptors, and characterize how GBV-C E2 modulates cellular cytokines, chemokines and receptors. Preliminary data have identified candidate receptors, and two of the five initial candidates are lymphocyte surface proteins that are important in both HIV replication and host immune responses. We propose four aims to further identify candidate receptors, validate that these receptors interact with E2, and we will assess the effect of E2 and GBV-C particle interaction with lymphocytes (both replicating and not) on chemokine receptor expression, T cell activation, and induction of anti-HIV chemokines. Finally, we will begin characterization of the domain within E2 that is responsible for binding and modulating T cell receptor expression. This information has the potential to facilitate development of cellular-based, anti-HIV and immunomodulatory treatments.

Public Health Relevance

The VA healthcare system is the largest provider for HIV-infection people in the United States, and although HIV can now be managed by antiretroviral therapy (ART), ART is expensive, has significant side effects, and resistance develops easily, particularly in patients who are not strictly adherent to therapy. GB virus C is a common human virus that does not appear to cause any disease, and studies show that it grows in the same cells as HIV resulting in inhibition of HIV replication. This application proposes to study how one of the GBV-C virus proteins (E2) modifies T cells so that HIV does not grow as well, and will serve as the basis for developing new approaches to HIV therapy.

Agency
National Institute of Health (NIH)
Institute
Veterans Affairs (VA)
Type
Non-HHS Research Projects (I01)
Project #
5I01BX000207-04
Application #
8258626
Study Section
Infectious Diseases A (INFA)
Project Start
2009-04-01
Project End
2013-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
4
Fiscal Year
2012
Total Cost
Indirect Cost
Name
Iowa City VA Medical Center
Department
Type
DUNS #
028084333
City
Iowa City
State
IA
Country
United States
Zip Code
52245
Malherbe, Delphine C; Mendy, Jason; Vang, Lo et al. (2018) Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. J Virol 92:
Fama, Angelo; Xiang, Jinhua; Link, Brian K et al. (2018) Human Pegivirus infection and lymphoma risk and prognosis: a North American study. Br J Haematol 182:644-653
Welch, Jennifer L; Kaddour, Hussein; Schlievert, Patrick M et al. (2018) Semen exosomes promote transcriptional silencing of HIV-1 by disrupting NF-kB/Sp1/Tat circuitry. J Virol :
Simmonds, Peter; Becher, Paul; Bukh, Jens et al. (2017) ICTV Virus Taxonomy Profile: Flaviviridae. J Gen Virol 98:2-3
Baer, Alan; Colon-Moran, Winston; Xiang, Jinhua et al. (2017) Src-family kinases negatively regulate NFAT signaling in resting human T cells. PLoS One 12:e0187123
Smith, Donald B; Meyers, Gregor; Bukh, Jens et al. (2017) Proposed revision to the taxonomy of the genus Pestivirus, family Flaviviridae. J Gen Virol 98:2106-2112
Bhattarai, Nirjal; McLinden, James H; Xiang, Jinhua et al. (2017) Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo. PLoS Pathog 13:e1006232
McLinden, James H; Bhattarai, Nirjal; Stapleton, Jack T et al. (2017) Yellow Fever Virus, but Not Zika Virus or Dengue Virus, Inhibits T-Cell Receptor-Mediated T-Cell Function by an RNA-Based Mechanism. J Infect Dis 216:1164-1175
Siewe, Basile; Nipper, Allison J; Sohn, Haewon et al. (2017) FcRL4 Expression Identifies a Pro-inflammatory B Cell Subset in Viremic HIV-Infected Subjects. Front Immunol 8:1339
DeLeon, Orlando; Hodis, Hagit; O'Malley, Yunxia et al. (2017) Accurate predictions of population-level changes in sequence and structural properties of HIV-1 Env using a volatility-controlled diffusion model. PLoS Biol 15:e2001549

Showing the most recent 10 out of 21 publications